Humacyte reported third quarter 2026 results characterized by a significant top-line beat and improved earnings versus expectations, driven by the rapid commercial scale-up of Symvess. Management indicated that momentum has accelerated into the current period, with early fourth quarter sales already approaching total third quarter levels.
Key Highlights
- Symvess sales reached $1.0 million in the third quarter, representing a 151% sequential increase from the second quarter of 2026.
- Hospital adoption of Symvess expanded to 49 facilities by September 30, 2026, a 44% increase from the 34 hospitals ordering at the end of June.
- The company reported October 2026 sales of $0.8 million and currently anticipates doubling its third quarter sales revenue during the fourth quarter of 2026.